Michael Partridge | Vertex Pharmaceuticals, Inc. |
Jeffrey M. Leiden, M.D., Ph.D. | Vertex Pharmaceuticals, Inc. |
Reshma Kewalramani | Vertex Pharmaceuticals, Inc. |
Ian F. Smith | Vertex Pharmaceuticals, Inc. |
Stuart A. Arbuckle | Vertex Pharmaceuticals, Inc. |
Geoffrey C. Porges | Leerink Partners LLC |
Geoffrey Meacham | Barclays Capital, Inc. |
Michael J. Yee | Jefferies LLC |
Ying Huang | Bank of America Merrill Lynch |
Terence Flynn | Goldman Sachs & Co. LLC |
Brian Abrahams | RBC Capital Markets LLC |
Phil Nadeau | Cowen & Company |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Shawn Fu | JPMorgan Securities LLC |
Dane Leone | BTIG LLC |
Carter Gould | UBS Securities LLC |
Alethia Young | Credit Suisse Securities (NYSE:USA) LLC |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Good day, ladies and gentlemen, and welcome to the Vertex Pharmaceuticals First Quarter 2018 Conference Call.
As a reminder, today's conference may be recorded. There will be a brief pause and then the conference will begin.
Good evening. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex.